# Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

> **NCT00431054** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Perifosine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00431054
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2016-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431054, "Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00431054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*